SCHEMBL6501428

SCHEMBL6501428

Cc1ccccc1C(C=O)c1ccncc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
ESR1 P03372 1/20 0.37
ACP3 P15309 1/20 0.37
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TYK2 P29597 1/20 0.35
KDM4E B2RXH2 2/20 0.35
TSHR P16473 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP3A4 P08684 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
ADRA2C P18825 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515739 0.85 ACP3 (0.49) GAASLC6A2SLC6A4SLC6A3ESR1
SCHEMBL10042124 0.82 ALDH1A1 (0.47) GAASLC6A2SLC6A4SLC6A3ESR1
SCHEMBL6506735 0.82 GAA (0.60) GAASLC6A2SLC6A4SLC6A3ACP3
SCHEMBL7042926 0.81 ESR1 (0.48) GAASLC6A2SLC6A4SLC6A3ESR1
SCHEMBL6502655 0.80 CYP19A1 (0.42) MAPTKDM4ETSHRCYP1A2CYP2D6
SCHEMBL5317299 0.79 MAPKAPK2 (0.40) GAASLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL3398965 0.79 CYP19A1 (0.39) SLC6A2SLC6A4SLC6A3ACP3ALDH1A1
SCHEMBL1515763 0.77 SLC6A3 (0.58) GAASLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL16062471 0.77 CYP1A2 (0.42) SLC6A2SLC6A4SLC6A3ALDH1A1MAPT
SCHEMBL6504970 0.74 CYP19A1 (0.39) GAASLC6A2SLC6A4SLC6A3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed
EP-1027050-A2 ADENOSINE A3 RECEPTOR ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2000-08-16 EP disclosed
WO-1999021555-A2 ADENOSINE A3 RECEPTOR ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 GAA 2036/4885SLC6A2 4327/4885SLC6A4 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.